Home > Resources and Support > For Pharmacists

For Pharmacists

Get product highlights on GAMMAGARD LIQUID to help determine if it might be the right choice for the patients you serve.


  • GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is stabilized and buffered with glycine for those patients in whom these additives may be a concern
  • Formulated with patient needs in mind, and with no additives1,2
  • Designed for ease of use with the broadest vial selection including a 30-gram vial
  • Brought to you by Shire, a source of IgG treatment for more than 25 years3

Download our PDF for more
detailed product highlights

 Download Product Highlights

 Download Full Prescribing Information

Order by calling 1-800-423-2090

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014. 2. Church JA, Leibl H, Stein MR, et al, and the US-PID-IGIV 10%-Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-395. 3. The Marketing Research Bureau. The Plasma Fractions Market in the United States 2011. Orange, CT: Marketing Research Bureau; 2012.

  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Clinical Study Video Learn more about the clinical study of the subcutaneous administration of GAMMAGARD LIQUID.
    View study presentation

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to